GLP-1 Drugs Are Moving Far Beyond Weight Loss — and Rewriting Chronic Disease Treatment

Why GLP-1s Are No Longer Just a Weight-Loss Story

GLP-1 medicines such as semaglutide—sold as Ozempic for diabetes and Wegovy for obesity—built their reputation on weight loss. But a quiet accumulation of clinical evidence is now pushing the drug class into a far larger role: treating or reducing the burden of chronic diseases that often travel with excess weight, from sleep apnea to kidney failure.

The timing of national data adds weight to the story, though not proof. Gallup’s self-reported obesity measure fell to 36.4 percent in its latest reading from a peak of 39.9 percent in 2022, while the share of adults saying they currently use a GLP-1 for weight loss rose from 3 percent in 2024 to 11 percent in 2026—about 29 million people. Because this is self-reported and observational, it cannot establish causation; the CDC’s measured survey, by contrast, put age-adjusted adult obesity at 40.3 percent between 2013 and 2023.

More striking are the trial results in conditions outside obesity. In two year-long studies of 469 people with sleep apnea, tirzepatide—the molecule in Mounjaro and Zepbound—cut breathing interruptions by more than half, and about half of participants ended with no apnea or enough improvement to stop being tired all day. In a 3,533-person trial of people with type 2 diabetes and chronic kidney disease, semaglutide reduced a composite of kidney failure, major function loss, or kidney- or cardiovascular-related death by 24 percent and lowered all-cause mortality by 20 percent over a median of 3.4 years.

Other trials point in the same direction. A liver study of 800 people with fatty, inflamed and scarred livers found inflammation cleared in nearly 63 percent on semaglutide after 72 weeks, versus 34 percent on placebo. A 407-person knee osteoarthritis trial recorded a 41.7-point drop on the WOMAC pain scale, against 27.5 for placebo. And a 17,604-person cardiovascular study in people who were overweight or obese but did not have diabetes found a 20 percent reduction in major cardiovascular events.

What Expanding GLP-1 Evidence Means for Patients, Payers and Drugmakers

From diabetes treatment to multi-organ intervention

Semaglutide was originally approved for type 2 diabetes, and only after earlier GLP-1 drugs showed substantial appetite and weight effects did Novo Nordisk test a higher dose that became Wegovy in 2021. The emerging data suggest the drug class acts on biological pathways relevant beyond glucose and appetite, which is why researchers are now measuring outcomes in kidneys, liver, heart, joints and sleep. That does not make GLP-1s a cure-all; it makes them a serious candidate for treating several conditions that often coexist.

The market and payer math is changing

Expanded use creates tension between clinical benefit and cost. A 2025 KFF poll found 56 percent of adults who had ever used a GLP-1 said the drugs were difficult to afford, and 27 percent had insurance but paid the full cost themselves. In a Cleveland Clinic review of 288 adults without diabetes who stopped injectable semaglutide or tirzepatide within a year, 47.6 percent stopped because of cost or insurance problems, compared with 14.6 percent because of side effects. An oral GLP-1 approved in April, starting at $149 per month for cash-paying patients, and Medicare’s July trial pricing of $50 per month for some GLP-1s are early responses to that barrier.

Where the evidence falls short

The drugs have not delivered on every hope. Novo Nordisk’s Alzheimer’s trial showed no evidence of slowing clinical progression. A Harvard team that pooled 48 placebo-controlled trials covering 94,245 people found little to no effect on thyroid, breast or kidney cancer risk, with FDA boxed warnings reflecting remaining uncertainty around some cancers. Known concerns also persist: across 22 randomized trials, roughly 25 percent of weight lost on GLP-1s was lean muscle mass, which matters more for older adults.

Stigma still distorts the conversation

Rice University researchers found that people judge a GLP-1 user more harshly than someone who never lost weight at all. That cultural reaction collides with a medical story that is increasingly about organ protection rather than appearance. The result is a mismatch: many patients who might benefit from these drugs are not being discussed in terms of sleep apnea, kidney function or heart risk, but through a moral lens around body size.

What the GLP-1 Shift Means for Patients, Clinicians and Payers

For patients and clinicians, the emerging evidence changes the decision framework. The steps below are drawn directly from the trial data, cost figures and documented limitations in this story.

• Consider GLP-1s for overlapping conditions, not weight alone. Patients with obesity plus sleep apnea, chronic kidney disease, fatty liver or elevated cardiovascular risk should ask whether a GLP-1 could address several conditions at once, based on the trial outcomes cited above.
• Plan for cost before starting therapy. Nearly half of adults without diabetes in one review stopped injectable GLP-1s within a year because of cost or insurance problems. Compare the new oral option at $149 per month cash and Medicare’s $50 per month trial pricing for some GLP-1s against insurance coverage.
• Protect muscle mass. About 25 percent of weight lost on GLP-1s appears to be lean mass. Patients—especially older adults—should talk to clinicians about resistance exercise and protein intake rather than treating weight loss as the only goal.
• Do not expect Alzheimer’s or broad cancer prevention benefits. A Novo Nordisk Alzheimer’s trial found no slowing of clinical progression, and pooled placebo-controlled data showed little effect on thyroid, breast or kidney cancer risk.
• For insurers and health systems, evaluate total disease cost, not just drug cost. Expanded indications may raise prescription spending, but the same data show reductions in kidney failure, cardiovascular events and sleep apnea severity. Payers should model offsets across those conditions using the trial outcomes and monitor adherence alongside access.